Immune checkpoint inhibition in sarcomas: time to be histology-specific?

Lancet Oncol. 2022 Sep;23(9):1111-1112. doi: 10.1016/S1470-2045(22)00500-9.

Authors

Andrea Napolitano¹, Paul H Huang², Robin L Jones³, Chongqi Tu⁴

Affiliations

¹ Sarcoma Unit, Royal Marsden NHS Foundation Trust, London, UK.
² The Institute of Cancer Research, London, UK.
³ Sarcoma Unit, Royal Marsden NHS Foundation Trust, London, UK; The Institute of Cancer Research, London, UK.
⁴ Orthopaedic Research Institute, West China Hospital, Sichuan University, 610041 Sichuan, China. Electronic address: tucq@scu.edu.cn.

PMID: 36055298
DOI: 10.1016/S1470-2045(22)00500-9

No abstract available

Publication types

Comment

MeSH terms

Humans
Immune Checkpoint Inhibitors
Immunotherapy
Sarcoma* / drug therapy
Soft Tissue Neoplasms*

Substances

Immune Checkpoint Inhibitors